Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX) provides integrated, temperature-controlled supply chain solutions for life sciences, with a particular focus on cell and gene therapies. Its services support the storage, handling and transport of biological materials for biotechnology and pharmaceutical companies, contract research and… From the company’s description.
Over the twelve months to Sep 30, 2026, Cryoport, Inc. reported revenue of $192.44M and a net loss of $41.30M. Its operating margin was −20.0%, and operations generated $11.00M in cash. In fiscal 2025, it reported revenue of $176.18M and net income of $78.30M.
Dotted labels explain each measure. is shown separately from the annual figures.
What Cryoport, Inc. does
In the company’s own words
Cryoport, Inc. (Nasdaq: CYRX) provides integrated, temperature-controlled supply chain solutions for life sciences, with a particular focus on cell and gene therapies. Its services support the storage, handling and transport of biological materials for biotechnology and pharmaceutical companies, contract research and development organizations, laboratories, fertility clinics, animal health companies, universities and research institutions. The company operates two reportable segments: Life Sciences Services, which accounted for 54.8% of 2025 revenue, and Life Sciences Products, which accounted for 45.2%. Services include temperature-controlled logistics, biostorage, bioprocessing, kitting, labeling, clinical sample management and cryopreservation; the products segment manufactures cryogenic freezers, dewars and transport systems through MVE Biological Solutions. Its Cryoportal platform supports digital logistics management and shipment tracking. In 2025, Cryoport reported revenue of $176.2 million and had 738 employees. Following its 2025 divestiture of specialty courier CRYOPDP, its continuing operations are organized around Cryoport Systems, CryoGene and MVE. Its website is www.cryoportinc.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BRENTWOOD, TN
- Fiscal year end
- December
- CIK
- 1124524
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cryoport, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cryoport, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Cryoport, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Cryoport, Inc.’s debt, $2.14M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.75%, maturing 2026 to 2026.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cryoport, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cryoport, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cryoport, Inc.'s last four quarterly filings that the numbers alone won't show?”